Intraoperative Staging and Surgical Management of Stage IIIA/N2 Non-Small Cell Lung Cancer

Igor Brichkov, Steven M. Keller

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Thorough staging of the mediastinum is an integral component of the operative treatment of non-small-cell lung cancer. Systematic sampling and systematic lymph node dissection provide similar and accurate staging information; however, systematic lymph node dissection is more likely to identify multiple levels of N2 disease and may be associated with improved survival. Although every effort should be made to identify N2 disease before surgery, if intraoperative metastases to mediastinal lymph nodes are discovered, the planned operation should proceed. Cisplatin-based adjuvant chemotherapy has moderate but proven survival benefit after resection of N2 disease. The role of postoperative radiotherapy remains uncertain.

Original languageEnglish (US)
Pages (from-to)381-391
Number of pages11
JournalThoracic Surgery Clinics
Volume18
Issue number4
DOIs
StatePublished - Nov 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Lymph Node Excision
Mediastinum
Adjuvant Chemotherapy
Cisplatin
Radiotherapy
Lymph Nodes
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Intraoperative Staging and Surgical Management of Stage IIIA/N2 Non-Small Cell Lung Cancer. / Brichkov, Igor; Keller, Steven M.

In: Thoracic Surgery Clinics, Vol. 18, No. 4, 11.2008, p. 381-391.

Research output: Contribution to journalArticle

Brichkov, Igor ; Keller, Steven M. / Intraoperative Staging and Surgical Management of Stage IIIA/N2 Non-Small Cell Lung Cancer. In: Thoracic Surgery Clinics. 2008 ; Vol. 18, No. 4. pp. 381-391.
@article{aa1fc06372b8487a84f60362d881e540,
title = "Intraoperative Staging and Surgical Management of Stage IIIA/N2 Non-Small Cell Lung Cancer",
abstract = "Thorough staging of the mediastinum is an integral component of the operative treatment of non-small-cell lung cancer. Systematic sampling and systematic lymph node dissection provide similar and accurate staging information; however, systematic lymph node dissection is more likely to identify multiple levels of N2 disease and may be associated with improved survival. Although every effort should be made to identify N2 disease before surgery, if intraoperative metastases to mediastinal lymph nodes are discovered, the planned operation should proceed. Cisplatin-based adjuvant chemotherapy has moderate but proven survival benefit after resection of N2 disease. The role of postoperative radiotherapy remains uncertain.",
author = "Igor Brichkov and Keller, {Steven M.}",
year = "2008",
month = "11",
doi = "10.1016/j.thorsurg.2008.08.003",
language = "English (US)",
volume = "18",
pages = "381--391",
journal = "Thoracic Surgery Clinics",
issn = "1547-4127",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Intraoperative Staging and Surgical Management of Stage IIIA/N2 Non-Small Cell Lung Cancer

AU - Brichkov, Igor

AU - Keller, Steven M.

PY - 2008/11

Y1 - 2008/11

N2 - Thorough staging of the mediastinum is an integral component of the operative treatment of non-small-cell lung cancer. Systematic sampling and systematic lymph node dissection provide similar and accurate staging information; however, systematic lymph node dissection is more likely to identify multiple levels of N2 disease and may be associated with improved survival. Although every effort should be made to identify N2 disease before surgery, if intraoperative metastases to mediastinal lymph nodes are discovered, the planned operation should proceed. Cisplatin-based adjuvant chemotherapy has moderate but proven survival benefit after resection of N2 disease. The role of postoperative radiotherapy remains uncertain.

AB - Thorough staging of the mediastinum is an integral component of the operative treatment of non-small-cell lung cancer. Systematic sampling and systematic lymph node dissection provide similar and accurate staging information; however, systematic lymph node dissection is more likely to identify multiple levels of N2 disease and may be associated with improved survival. Although every effort should be made to identify N2 disease before surgery, if intraoperative metastases to mediastinal lymph nodes are discovered, the planned operation should proceed. Cisplatin-based adjuvant chemotherapy has moderate but proven survival benefit after resection of N2 disease. The role of postoperative radiotherapy remains uncertain.

UR - http://www.scopus.com/inward/record.url?scp=53649096558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649096558&partnerID=8YFLogxK

U2 - 10.1016/j.thorsurg.2008.08.003

DO - 10.1016/j.thorsurg.2008.08.003

M3 - Article

C2 - 19086607

AN - SCOPUS:53649096558

VL - 18

SP - 381

EP - 391

JO - Thoracic Surgery Clinics

JF - Thoracic Surgery Clinics

SN - 1547-4127

IS - 4

ER -